A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

Phase 2 Active not recruiting 62 enrolled Memorial Sloan Kettering Cancer Center

NaSequentialOpen-labelTreatment

This study is being done to see if the investigational drug, anakinra, prevent or reverse the severe side effects caused by CAR-T cell therapy.

Evaluation	Drug	Modality	Dose	Route
Subject	Anakinra	Protein / enzyme biologic	100 mg	Subcutaneous